- Community-Beiträge
- Aktuellste Threads
| Aktienanzahl | 83,15 Mio. |
| Aktientyp | Stammaktie |
Lundbeck übernimmt ALDR für 2 Mrd. $
"To acquire Alder, Lundbeck has put together a deal worth $18 a share upfront, plus $2 a share tied to the approval of anti-CGRP antibody eptinezumab in Europe. Net of cash, the deal is valued at $1.95 billion.
At $18 a share, the upfront portion of the deal represents a 79% premium over Alder’s share price just prior to news of the takeover. Alder has traded above $18 within the past year, though. The slide in Alder’s share price, from highs of $18 a year ago to recent lows of around $8, covers a period in which doubts about its ability to compete in a highly competitive field have intensified."
https://www.fiercebiotech.com/biotech/lundbeck-pens-2b-alder-takeover-to-boost-brain-disease-pipeline
